Company Overview
About Agomab Therapeutics
Agomab Therapeutics went public on Nasdaq in February 2026, raising approximately $200 million at an ~$780 million valuation (ticker: AGMB), becoming one of the first European biotechs to list in the US in 2026. Agomab is developing ontunisertib — the only clinical-stage gut-restricted ALK5/TGFβR1 inhibitor for fibrostenosing Crohn's disease, a severe complication where intestinal fibrosis causes strictures requiring repeated surgery. The company also has AGMB-447 in Phase 1 for idiopathic pulmonary fibrosis (IPF), using lung-restricted delivery of the same mechanism.
Business Model & Competitive Advantage
Fibrostenosing Crohn's disease affects approximately 30% of Crohn's patients and has zero approved treatments specifically for the fibrotic complication — standard Crohn's therapies address inflammation but not the fibrotic strictures that cause bowel obstruction. Ontunisertib's gut-restricted delivery (not absorbed systemically) targets the fibrotic process directly in intestinal tissue while avoiding the systemic side effects that broad TGFβ inhibition causes.
Competitive Landscape 2025–2026
The dual-indication strategy using lung-restricted versus gut-restricted delivery of the same ALK5 inhibitory mechanism provides clinical efficiency: positive proof-of-concept data in one indication validates the mechanism for the other, and the development infrastructure for both programs is largely shared. Agomab's Nasdaq listing provides capital market access for both development programs simultaneously.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Agomab Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Agomab Therapeutics has achieved $200M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Agomab Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Agomab Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Agomab Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Agomab Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →